SCHEMBL6372065

SCHEMBL6372065

CCCCCCCCCCCCCCCC(=O)NC(Cc1ccccc1)C(=O)O

nearest known ligand 0.81

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ FAAH O00519 2/20 0.81
▸ ITGB3 P05106 2/20 0.65
▸ ITGA2B P08514 2/20 0.65
▸ PSMB5 P28074 2/20 0.64
▸ HDAC3 O15379 1/20 0.60
▸ HDAC4 P56524 1/20 0.60
▸ HDAC1 Q13547 1/20 0.60
▸ HDAC7 Q8WUI4 1/20 0.60
▸ HDAC2 Q92769 1/20 0.60
▸ HDAC10 Q969S8 1/20 0.60
▸ HDAC11 Q96DB2 1/20 0.60
▸ HDAC8 Q9BY41 1/20 0.60
▸ HDAC6 Q9UBN7 1/20 0.60
▸ HDAC9 Q9UKV0 1/20 0.60
▸ HDAC5 Q9UQL6 1/20 0.60
▸ NOD1 Q9Y239 1/20 0.58
▸ EPHX2 P34913 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6553283 1.00 FAAH (0.81) FAAHITGB3ITGA2BPSMB5HDAC3
SCHEMBL6372057 1.00 FAAH (0.81) FAAHITGB3ITGA2BPSMB5HDAC3
SCHEMBL6730310 1.00 FAAH (0.81) FAAHITGB3ITGA2BPSMB5HDAC3
SCHEMBL17204255 1.00 FAAH (0.81) FAAHITGB3ITGA2BPSMB5HDAC3
SCHEMBL9666121 1.00 FAAH (0.81) FAAHITGB3ITGA2BPSMB5HDAC3
SCHEMBL22494096 1.00 FAAH (0.81) FAAHITGB3ITGA2BPSMB5HDAC3
SCHEMBL22494095 1.00 FAAH (0.81) FAAHITGB3ITGA2BPSMB5HDAC3
SCHEMBL21998924 1.00 FAAH (0.81) FAAHITGB3ITGA2BPSMB5HDAC3
SCHEMBL22494097 1.00 FAAH (0.81) FAAHITGB3ITGA2BPSMB5HDAC3
SCHEMBL9716614 1.00 FAAH (0.81) FAAHITGB3ITGA2BPSMB5HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3368157-A2 METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND TREATMENT OF METABOLIC DISORDERS USING PM20D1 AND N-LIPIDATED AMINO ACIDS Dana-Farber Cancer Institute, Inc. (US) 2018-09-05 — — EP claimed
WO-2017075329-A2 METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND TREATMENT OF METABOLIC DISORDERS USING PM20D1 AND N-LIPIDATED AMINO ACIDS DANA-FARBER CANCER INSTITUTE, INC. (US) 2017-05-04 — — WO claimed
EP-0473700-A1 AN ENZYME-CATALYZED PROCESS FOR PREPARING N-ACYL AMINO ACIDS AND N-ACYL AMINO ACID AMIDES NOVO NORDISK A/S (DK) 1992-03-11 — — EP claimed
WO-1990014429-A1 AN ENZYME-CATALYZED PROCESS FOR PREPARING N-ACYL AMINO ACIDS AND N-ACYL AMINO ACID AMIDES NOVO NORDISK A/S (DK) 1990-11-29 — — WO claimed
CN-120053660-A Hydrophilic complex for preventing, preventing or treating microbial infection, preparation and application thereof 太阳雨林(北京)生物医药有限公司 2025-05-30 — — CN disclosed
CN-120053661-A Hydrophilic fatty acid complex for preventing, preventing or treating microbial infection, preparation and application thereof 太阳雨林(北京)生物医药有限公司 2025-05-30 — — CN disclosed
CN-119855607-A Carbon chain substance for regulating transmembrane transport and fluidity of cell membrane, preparation and application 太阳雨林(北京)生物医药有限公司 2025-04-18 — — CN disclosed
US-12194080-B2 Methods for identification, assessment, prevention, and treatment of metabolic disorders using PM20D1 and N-lipidated amino acids DANA-FARBER CANCER INSTITUTE, INC. (US) 2025-01-14 — — US disclosed
CN-116926140-A A fatty acylated amino acid with effect of enhancing or improving food taste, and its preparation method 华南理工大学 2023-10-24 — — CN disclosed
CN-115607677-A Compound for preventing, preventing or treating microbial infection and preparation and application thereof 太阳雨林(北京)生物医药有限公司 2023-01-17 — — CN disclosed
CN-114569726-B Compound for preventing, preventing or treating microbial infection and preparation method and application thereof 太阳雨林(北京)生物医药有限公司 2022-10-28 — — CN disclosed
CN-114788872-A Compound for preventing, preventing or treating microbial infection and preparation and application thereof 太阳雨林(北京)生物医药有限公司 2022-07-26 — — CN disclosed
WO-2017075329-A2 METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND TREATMENT OF METABOLIC DISORDERS USING PM20D1 AND N-LIPIDATED AMINO ACIDS DANA-FARBER CANCER INSTITUTE, INC. (US) 2017-05-04 — — WO disclosed
US-20050069513-A1 Amphiphilic compounds for pharmaceutical or cosmetic use PHYSICA S.A.R.L. (FR) 2005-03-31 — — US disclosed
EP-1458415-A2 AMPHIPHILIC COMPOUNDS FOR PHARMACEUTICAL OR COSMETIC USE Physica S.A.R.L. (FR) 2004-09-22 — — EP disclosed
WO-2003055528-A2 AMPHIPHILIC COMPOUNDS FOR PHARMACEUTICAL OR COSMETIC USE PHYSICA S.A.R.L. (FR) 2003-07-10 — — WO disclosed
EP-0473700-A1 AN ENZYME-CATALYZED PROCESS FOR PREPARING N-ACYL AMINO ACIDS AND N-ACYL AMINO ACID AMIDES NOVO NORDISK A/S (DK) 1992-03-11 — — EP disclosed
WO-1990014429-A1 AN ENZYME-CATALYZED PROCESS FOR PREPARING N-ACYL AMINO ACIDS AND N-ACYL AMINO ACID AMIDES NOVO NORDISK A/S (DK) 1990-11-29 — — WO disclosed
US-4016287-A COSMETIC AND ANTIINFLAMMATORY BOEHRINGER INGELHEIM GMBH (DT) 1977-04-05 — — US disclosed
US-3971701-A FATTY ACID, ESTER OR N-ACYLAMINO ACID SURFACTANT AJINOMOTO CO., INC. (JA) 1976-07-27 — — US disclosed
Send feedback